Compare Immunovant Inc. Common Stock (IMVT) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs NICE Ltd — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while NICE Ltd trades at $117.31 (market cap $6.83B). The key difference: Immunovant Inc. Common Stock and NICE Ltd are close in size by market cap, and NICE Ltd is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and NICE Ltd for 15 Days on average.
| IMVT | NICE | |
|---|---|---|
Market Cap | $6.62B | $6.83B |
Volume | 1,131,364 | 444,610 |
Sector | Health | Technology |
52-Week High | $44.96 | $137.68 |
52-Week Low | $17.03 | $83.15 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $5.72B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NICE (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $2.95 billion in 2025, though net income is projected to decline in 2026. Recent news highlights leadership in AI-driven contact center platforms and positive institutional buying interest.
The outlook for NICE is positive, supported by AI revenue growth and a reasonable valuation, but investors face risks from margin compression and earnings volatility. The stock's proximity to resistance at $118 suggests near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
